OnePin Peptide Library · Metabolic
Cagrilintide
Cagri
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk for the treatment of obesity and weight management. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells that plays a role in appetite regulation, gastric emptying, and postprandial glucose control. Cagrilintide has been engineered with fatty acid acylation to extend its half-life, enabling once-weekly subcutaneous dosing.,Cagrilintide has been studied as a standalone agent and in combination with semaglutide (the combination known as CagriSema). Phase 2 and Phase 3 clinical trials have demonstrated significant weight loss, with the CagriSema combination showing particularly robust results, achieving greater weight reduction than either agent alone.,As of 2025, cagrilintide is not yet independently FDA-approved, though the CagriSema combination is in late-stage clinical development. Novo Nordisk has filed for regulatory approval of CagriSema. Cagrilintide represents a novel mechanism complementary to GLP-1 receptor agonists, targeting the amylin pathway for appetite and metabolic control.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Activates amylin receptors (calcitonin receptor plus RAMP1/2/3 complexes) in the area postrema and hypothalamus, promoting satiety and reducing food intake.,Slows gastric emptying, which contributes to prolonged feelings of fullness after meals and reduces postprandial glucose excursions.,May modulate glucagon secretion, reducing hepatic glucose output and contributing to improved glycemic control.
Activates amylin receptors (calcitonin receptor plus RAMP1/2/3 complexes) in the area postrema and hypothalamus, promoting satiety and reducing food intake.,Slows gastric emptying, which contributes to prolonged feelings of fullness after meals and reduces postprandial glucose excursions.,May modulate glucagon secretion, reducing hepatic glucose output and contributing to improved glycemic control.
What to expect
Weeks 1-4: Appetite changes begin during dose escalation. GI side effects most common in this period. Weight loss of 1-3% may occur.
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Safe & synergistic
Pharmacokinetics
Storage. Store refrigerated at 2-8C.
Regulatory status
Investigational - not yet independently FDA-approved. CagriSema (cagrilintide + semaglutide combination) is in late-stage regulatory review by Novo Nordisk. Breakthrough therapy potential recognized.
Put it to work
Calculate, log & track
Open Cagrilintide straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Cagrilintide in the app →Go deeper
The guide & community
The complete Cagrilintide walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗